

# Randomized Trial of Lifestyle Modification and Pharma

New England Journal of Medicine

353, 2111-2120

DOI: [10.1056/nejmoa050156](https://doi.org/10.1056/nejmoa050156)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long-term pharmacotherapy for obesity and overweight. The Cochrane Library, 2003, , CD004094.	1.5	160
2	Pharmacotherapy for Obesity â€” Promise and Uncertainty. New England Journal of Medicine, 2005, 353, 2187-2189.	13.9	44
3	An observational examination of the literature in diagnostic anatomic pathology. Seminars in Diagnostic Pathology, 2005, 22, 126-138.	1.0	10
4	Opinion and Evidence for Treatments in Endocrine Disorders. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 59-63.	1.8	0
5	Enhancing early uptake of drug evidence into primary care. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 661-671.	0.7	7
6	Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications. Drugs and Therapy Perspectives, 2006, 22, 7-11.	0.3	3
7	Sibutramine for obesity in adolescents. Expert Opinion on Pharmacotherapy, 2006, 7, 2435-2438.	0.9	2
8	La eficacia de varias dietas adelgazantes comercializadas en Reino Unido es similar. Las diet trials de la BBC. FMC Formacion Medica Continuada En Atencion Primaria, 2006, 13, 502.	0.0	0
9	Preventing Cardiovascular Disease and Diabetes. Circulation, 2006, 113, 2943-2946.	1.6	242
10	Assessment and Preparation of Patients for Bariatric Surgery. Mayo Clinic Proceedings, 2006, 81, S11-S17.	1.4	82
11	Renal Disease in Obesity: The Need for Greater Attention. , 2006, 16, 216-223.		87
12	Role of lifestyle modification in the management of polycystic ovary syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 293-310.	2.2	68
13	The Art of Health Promotion. American Journal of Health Promotion, 2006, 21, TAHP-1-TAHP-12.	0.9	4
14	Can we predict treatment response to antiobesity medication?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 314-315.	2.9	0
15	Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. Yearbook of Endocrinology, 2006, 2006, 161-164.	0.0	0
16	Obesity, proteinuria and progression of renal failure. Current Opinion in Nephrology and Hypertension, 2006, 15, 481-486.	1.0	123
17	Obstetric Outcomes After In Vitro Fertilization in Obese and Morbidly Obese Women. Obstetrics and Gynecology, 2006, 108, 61-69.	1.2	205
18	Obesity. Cardiology in Review, 2006, 14, 238-258.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Pharmacologic Treatment of Obesity. Topics in Clinical Nutrition, 2006, 21, 10-16.	0.2	0
20	Assessment and Management of Obesity. Obstetrical and Gynecological Survey, 2006, 61, 742-748.	0.2	3
21	The obesity epidemic and its cardiovascular consequences. Current Opinion in Cardiology, 2006, 21, 353-360.	0.8	87
22	Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International Journal of Clinical Practice, 2006, 60, 1697-1706.	0.8	35
23	Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. Journal of Internal Medicine, 2006, 260, 388-398.	2.7	43
24	The Evolution of Very-Low-Calorie Diets: An Update and Meta-Analysis. Obesity, 2006, 14, 1283-1293.	1.5	325
25	Use of Lifestyle Changes Treatment Plans and Drug Therapy in Controlling Cardiovascular and Metabolic Risk Factors. Obesity, 2006, 14, 135S-142S.	1.5	24
26	Clinical Implications for the Treatment of Obesity. Obesity, 2006, 14, 182S-185S.	1.5	17
27	The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It. Obesity, 2006, 14, 737-752.	1.5	714
28	A Self-Regulation Program for Maintenance of Weight Loss. New England Journal of Medicine, 2006, 355, 1563-1571.	13.9	720
29	Self-management in lower urinary tract symptoms: the next major therapeutic revolution. World Journal of Urology, 2006, 24, 371-377.	1.2	5
30	Clinical trials report. Current Diabetes Reports, 2006, 6, 227-229.	1.7	0
31	Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient. Current Treatment Options in Gastroenterology, 2006, 9, 423-431.	0.3	26
32	Role of the Pharmacist. Pharmacotherapy, 2006, 26, 227S-232S.	1.2	7
33	Clinical significance of postprandial hyperglycemia. Drug Development Research, 2006, 67, 587-590.	1.4	3
34	Dietary and Body Weight Control: Therapeutic Education, Motivational Interviewing and Cognitive-Behavioral Approaches for Long-Term Weight Loss Maintenance. , 2006, 11, 127-137.		5
35	Weight Loss and Proteinuria. , 2006, 151, 221-229.		20
36	Management: Part II "Drugs. BMJ: British Medical Journal, 2006, 333, 794-797.	2.4	31

#	ARTICLE	IF	CITATIONS
38	A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents. <i>American Journal of Psychiatry</i> , 2006, 163, 2072-2079.	4.0	218
40	Pharmacotherapy of Obesity. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 475-484.	0.6	14
41	MEDICAL MANAGEMENT OF OBESITY. <i>Acta Clinica Belgica</i> , 2006, 61, 286-294.	0.5	5
42	Maternal Weight Gain Is Associated With Infant Insulin Concentrations During the 1st Year of Life. <i>Diabetes Care</i> , 2006, 29, 949-949.	4.3	3
43	Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 251-260.	0.6	15
44	Obesity Research—Limitations of Methods, Measurements, and Medications. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 826.	3.8	59
45	Preventing Cardiovascular Disease and Diabetes: A call to action from the American Diabetes Association and the American Heart Association. <i>Diabetes Care</i> , 2006, 29, 1697-1699.	4.3	90
46	Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks. <i>Circulation</i> , 2006, 114, 974-984.	1.6	91
47	Lifestyle Intervention and Coronary Heart Disease Risk Factor Changes over 18 Months in Postmenopausal Women: The Women On the Move through Activity And Nutrition (WOMAN Study) Clinical Trial. <i>Journal of Women's Health</i> , 2006, 15, 962-974.	1.5	77
48	Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome: Response to Azdbakht et al.. <i>Diabetes Care</i> , 2006, 29, 954-955.	4.3	14
49	Severe Injection Site Reaction to Insulin Detemir. <i>Diabetes Care</i> , 2006, 29, 946-946.	4.3	25
50	How successful are commercial weight-loss programs?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 658-659.	2.9	0
51	Probing the Validity of the Probe-to-Bone Test in the Diagnosis of Osteomyelitis of the Foot in Diabetes. <i>Diabetes Care</i> , 2006, 29, 945-945.	4.3	110
52	Clinical Investigations of Antiobesity Drugs. , 2007, , 337-III.		4
53	State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 367-388.	0.8	3
54	Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2007, 13, 2193-2198.	0.9	43
55	Melanocortin - 4 Receptor Agonists for the Treatment of Obesity. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1121-1130.	1.0	38
56	Medical Weight Loss Treatment Options in Obese Solid-Organ Transplant Candidates. <i>Nutrition in Clinical Practice</i> , 2007, 22, 505-511.	1.1	7

#	ARTICLE	IF	CITATIONS
57	Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders. <i>Current Nutrition and Food Science</i> , 2007, 3, 123-133.	0.3	6
58	Treatment of Infertility in the Polycystic Ovary Syndrome. <i>New England Journal of Medicine</i> , 2007, 356, 1999-2001.	13.9	7
59	Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. <i>European Heart Journal</i> , 2007, 28, 2915-2923.	1.0	128
60	Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2001-2009.	0.9	2
61	Pharmacological Treatment of the Overweight Patient. <i>Pharmacological Reviews</i> , 2007, 59, 151-184.	7.1	147
63	Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach. <i>Diabetes Care</i> , 2007, 30, 395-402.	4.3	75
64	Review: Pharmacotherapy as part of a weight management programme: a UK perspective. <i>British Journal of Diabetes and Vascular Disease</i> , 2007, 7, 268-277.	0.6	0
65	State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 457-481.	0.8	14
66	The Metabolic Syndrome and Cerebrovascular Disease: Suspicion and Evidence. <i>Cerebrovascular Diseases</i> , 2007, 24, 64-75.	0.8	9
67	Pharmacologic Treatment Options for Obesity: Current and Potential Medications. <i>Nutrition in Clinical Practice</i> , 2007, 22, 50-54.	1.1	12
68	Nurses at the cutting edge of obesity. <i>Practice Nursing</i> , 2007, 18, 454-458.	0.1	1
69	Food reinforcement and eating: A multilevel analysis.. <i>Psychological Bulletin</i> , 2007, 133, 884-906.	5.5	311
70	Effects of a vegetarian diet and treatment preference on biochemical and dietary variables in overweight and obese adults: a randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 588-596.	2.2	51
71	Two Year Reduction In Sleep Apnea Symptoms and Associated Diabetes Incidence After Weight Loss In Severe Obesity. <i>Sleep</i> , 2007, 30, 703-710.	0.6	128
72	Obesity and reproduction: impact and interventions. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 384-389.	0.9	68
73	Obesity and Lifestyle Management in Polycystic Ovary Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2007, 50, 277-294.	0.6	63
74	Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. <i>Yearbook of Vascular Surgery</i> , 2007, 2007, 84-86.	0.0	0
75	Treatment of Obesity. <i>Mayo Clinic Proceedings</i> , 2007, 82, 93-102.	1.4	108

#	ARTICLE	IF	CITATIONS
76	Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. <i>Public Health Nutrition</i> , 2007, 10, 1200-1205.	1.1	47
77	The link between abdominal obesity, metabolic syndrome and cardiovascular disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 319-326.	1.1	538
78	Obesity and kidney disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 757-762.	1.1	62
79	Therapeutic Options for Modifying Cardiometabolic Risk Factors. <i>American Journal of Medicine</i> , 2007, 120, S26-S34.	0.6	31
80	Medical Therapy for Obesity—Current Status and Future Hopes. <i>Medical Clinics of North America</i> , 2007, 91, 1225-1253.	1.1	18
81	Drug treatments for obesity: orlistat, sibutramine, and rimonabant. <i>Lancet, The</i> , 2007, 369, 71-77.	6.3	648
82	¿Cuándo estar indicado el tratamiento con sibutramina y durante cuánto tiempo?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2007, 14, 281-282.	0.0	0
86	Critical assessment of the current guidelines for the management and treatment of morbidly obese patients. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 844-852.	1.8	38
87	The Obesity Epidemic: Current and Future Pharmacological Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 565-592.	4.2	81
88	Treatment of Obesity. <i>Mayo Clinic Proceedings</i> , 2007, 82, 93-102.	1.4	48
89	Obesity Management. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 191-210.	1.0	12
90	Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 829-837.	2.4	33
91	The clinical effectiveness of weight loss drugs. <i>Obesity Research and Clinical Practice</i> , 2007, 1, 1-5.	0.8	12
92	Group behavior therapy versus individual behavior therapy for healthy dieting and weight control management in overweight and obese women living in rural community. <i>Obesity Research and Clinical Practice</i> , 2007, 1, 223-232.	0.8	24
93	Is prevention of Type-2 diabetes feasible and efficient in primary care?. <i>Primary Care Diabetes</i> , 2007, 1, 5-11.	0.9	29
96	Lifestyle Modification for the Management of Obesity. <i>Gastroenterology</i> , 2007, 132, 2226-2238.	0.6	328
97	Drug Treatment of the Overweight Patient. <i>Gastroenterology</i> , 2007, 132, 2239-2252.	0.6	107
98	Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies. <i>Journal of Clinical Lipidology</i> , 2007, 1, 575-582.	0.6	18

#	ARTICLE	IF	CITATIONS
99	Pharmacotherapeutic Options for Overweight Adolescents. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1445-1455.	0.9	37
100	Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 346-354.	2.2	195
101	Integrated Primary Prevention of Cardiovascular Disease. , 0, , 129-189.		0
103	Lifestyle Modification in the Treatment of Obesity: An Educational Challenge and Opportunity. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 776-779.	2.3	69
104	Obesity Pharmacotherapy from a Regulatory Perspective: Overview and Key Challenges. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 756-760.	2.3	5
105	Metabolic Syndrome: From Global Epidemiology to Individualized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 509-524.	2.3	138
106	Impact of weight loss on the metabolic syndrome. <i>International Journal of Obesity</i> , 2007, 31, 1442-1448.	1.6	74
107	The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity. <i>International Journal of Obesity</i> , 2007, 31, 1739-1745.	1.6	65
108	Failure to Meet Weight Loss Expectations Does Not Impact Maintenance in Successful Weight Losers**. <i>Obesity</i> , 2007, 15, 3086-3090.	1.5	36
109	Weight Loss Maintenance in Severely Obese Adults after an Intensive Lifestyle Intervention: 2 to 4 Year Follow-up. <i>Obesity</i> , 2007, 15, 413-420.	1.5	96
110	Disinhibition: its effects on appetite and weight regulation. <i>Obesity Reviews</i> , 2008, 9, 409-419.	3.1	290
111	Appetite and obesity: a gastroenterologist's perspective. <i>Neurogastroenterology and Motility</i> , 2007, 19, 333-341.	1.6	34
112	Screening and Behavioral Management: Obesity and Weight Management. <i>Headache</i> , 2008, 48, 51-57.	1.8	20
113	New agents in development for the management of obesity. <i>International Journal of Clinical Practice</i> , 2007, 61, 2103-2112.	0.8	15
114	Behavior Therapy and Cognitive-Behavioral Therapy of Obesity: Is There a Difference?. <i>Journal of the American Dietetic Association</i> , 2007, 107, 92-99.	1.3	126
115	Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction. <i>American Journal of Cardiology</i> , 2007, 99, 68-79.	0.7	113
116	Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Efficacy. <i>American Journal of Cardiology</i> , 2007, 100, S18-S26.	0.7	10
117	Overweight and obesity: Key components of cardiometabolic risk. <i>Clinical Cornerstone</i> , 2007, 8, 29-37.	1.0	45

#	ARTICLE	IF	CITATIONS
120	The role of nutrition therapy and dietitians in the management of the metabolic syndrome. <i>Current Diabetes Reports</i> , 2007, 7, 60-65.	1.7	9
121	Efficacy of lifestyle behavior change programs in diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 123-127.	1.7	10
122	Perceived Barriers to Weight Management in Primary Care—Perspectives of Patients and Providers. <i>Journal of General Internal Medicine</i> , 2007, 22, 518-522.	1.3	98
123	Obese African-American Women's Perspectives on Weight Loss and Bariatric Surgery. <i>Journal of General Internal Medicine</i> , 2007, 22, 908-914.	1.3	60
124	Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. <i>Clinical Biochemistry</i> , 2007, 40, 964-968.	0.8	95
125	Changes in self-efficacy and dietary adherence: the impact on weight loss in the PREFER study. <i>Journal of Behavioral Medicine</i> , 2008, 31, 81-92.	1.1	135
129	Endoscopic Ultrasound-Guided Gastric Botulinum Toxin Injections in Obese Subjects: A Pilot Study. <i>Obesity Surgery</i> , 2008, 18, 401-407.	1.1	42
130	Management of the metabolic syndrome in cardiovascular disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 27-38.	0.4	1
133	Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction. <i>Obesity</i> , 2008, 16, 59-63.	1.5	46
134	Compliance, Behavior Change, and Weight Loss With Orlistat in an Over-the-Counter Setting. <i>Obesity</i> , 2008, 16, 623-629.	1.5	30
135	Successful Weight-loss Maintenance in Relation to Method of Weight Loss. <i>Obesity</i> , 2008, 16, 2456-2461.	1.5	52
136	Weight maintenance, behaviors and barriers among previous participants of a university-based weight control program. <i>International Journal of Obesity</i> , 2008, 32, 519-526.	1.6	48
137	Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. <i>Diabetic Medicine</i> , 2008, 25, 1142-1150.	1.2	29
138	The Challenge of Treating Obesity: The Endocannabinoid System as a Potential Target. <i>Journal of the American Dietetic Association</i> , 2008, 108, 823-831.	1.3	12
139	Sexual Dysfunction Is Common in the Morbidly Obese Male and Improves after Gastric Bypass Surgery. <i>Journal of the American College of Surgeons</i> , 2008, 207, 859-864.	0.2	73
141	The Endocannabinoid System as a Target for Obesity Treatment. <i>Clinical Cornerstone</i> , 2008, 9, 52-66.	1.0	9
142	Clinical Research Abstracts for Pediatricians. <i>Journal of Pediatrics</i> , 2008, 153, 724-727.	0.9	0
143	Metformin may aid weight loss in overweight teenage girls. <i>Journal of Pediatrics</i> , 2008, 153, 725-726.	0.9	1



#	ARTICLE	IF	CITATIONS
144	No increase in cardiorespiratory events seen after diphtheria-tetanus-acellular pertussis immunization. <i>Journal of Pediatrics</i> , 2008, 153, 726.	0.9	0
145	Selective 5-HT <sub>6</sub> receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. , 2008, 117, 207-231.		174
146	Should overweight and obese primary care patients be offered a meal replacement diet?. <i>Obesity Research and Clinical Practice</i> , 2008, 2, 263-268.	0.8	5
147	Nonsurgical Management of Obesity in Adults. <i>New England Journal of Medicine</i> , 2008, 358, 1941-1950.	13.9	161
148	A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. <i>Gastroenterology</i> , 2008, 135, 1142-1154.	0.6	43
149	Î <sup>1</sup> FosB-Mediated Alterations in Dopamine Signaling Are Normalized by a Palatable High-Fat Diet. <i>Biological Psychiatry</i> , 2008, 64, 941-950.	0.7	64
150	An evidence-based review of the use of therapeutic foods, owner education, exercise, and drugs for the management of obese and overweight pets. <i>Journal of the American Veterinary Medical Association</i> , 2008, 233, 717-725.	0.2	28
151	Psychosocial Interventions for Chronic Pain. , 2008, , .		11
152	Medications for Weight Reduction. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 923-942.	1.2	21
153	Cognitive and Behavioral Approaches in the Treatment of Obesity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 905-922.	1.2	27
155	Effectiveness of a Structured Intensive Weight Loss Program Using Health Educators. <i>Disease Management and Health Outcomes</i> , 2008, 16, 449-454.	0.3	3
156	Effectiveness of Medifast supplements combined with obesity pharmacotherapy: A clinical program evaluation. <i>Eating and Weight Disorders</i> , 2008, 13, 95-101.	1.2	15
157	Sibutramine: Balancing weight loss benefit and possible cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 337-341.	1.1	29
158	Obesity in neurobiology. <i>Progress in Neurobiology</i> , 2008, 84, 85-103.	2.8	30
159	Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. <i>Fertility and Sterility</i> , 2008, 89, 1221-1228.	0.5	44
160	Consensus on infertility treatment related to polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2008, 89, 505-522.	0.5	637
161	Obesity and reproduction: an educational bulletin. <i>Fertility and Sterility</i> , 2008, 90, S21-S29.	0.5	111
162	Taking control of your personal eating and exercise environment: A weight maintenance program. <i>Eating Behaviors</i> , 2008, 9, 228-237.	1.1	24

#	ARTICLE	IF	CITATIONS
163	Using instrumented paper diaries to document self-monitoring patterns in weight loss. <i>Contemporary Clinical Trials</i> , 2008, 29, 182-193.	0.8	122
167	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 343-368.	0.6	423
168	The future of obesity: new drugs versus lifestyle interventions. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 263-267.	1.9	39
169	Sibutramine: current status as an anti-obesity drug and its future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2161-2173.	0.9	23
170	Nutrition and Gastrointestinal Disease. , 2008, , .		1
171	The value of current interventions for obesity. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, S3-S9.	3.3	13
172	Obesity and the Metabolic Syndrome in the Elderly – A Mini-Review. <i>Gerontology</i> , 2008, 54, 253-259.	1.4	76
173	Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. <i>Diabetes Care</i> , 2008, 31, 1816-1823.	4.3	129
174	Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, s81-s88.	1.8	97
175	Adult Obesity and Diet. <i>InnovAiT</i> , 2008, 1, 387-395.	0.0	2
176	Design and Reach of a Primary Care Weight Management Program. <i>Journal of Health Care for the Poor and Underserved</i> , 2008, 19, 171-179.	0.4	7
177	The Efficiency of Cellular Energy Transduction and Its Implications for Obesity. <i>Annual Review of Nutrition</i> , 2008, 28, 13-33.	4.3	109
178	Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2008, 15, 57-68.	5.2	87
179	Burden and Rates of Treatment and Control of Cardiovascular Disease Risk Factors in Obesity. <i>Diabetes Care</i> , 2008, 31, 1367-1372.	4.3	52
180	Diabetes and Obesity: Part 2. <i>Diabetes Care</i> , 2008, 31, 176-182.	4.3	2
181	Treatment Modalities of Obesity. <i>Diabetes Care</i> , 2008, 31, S269-S277.	4.3	169
182	Graphics and Ethos in Biomedical Journals. <i>Journal of Technical Writing and Communication</i> , 2008, 38, 111-131.	1.1	11
183	Extended-Care Programs for Weight Management in Rural Communities. <i>Archives of Internal Medicine</i> , 2008, 168, 2347.	4.3	227

#	ARTICLE	IF	CITATIONS
184	Comparison of Parent-Only vs Family-Based Interventions for Overweight Children in Underserved Rural Settings. <i>JAMA Pediatrics</i> , 2008, 162, 1119.	3.6	172
185	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 170-176.	0.6	2
186	Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. <i>Endoscopy</i> , 2008, 40, 406-413.	1.0	111
188	Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study. <i>American Journal of Psychiatry</i> , 2008, 165, 51-58.	4.0	126
189	Surgery for obesity in adults. <i>Drug and Therapeutics Bulletin</i> , 2008, 46, 41-45.	0.3	1
191	Robots at home: Understanding long-term human-robot interaction. , 2008, , .		199
192	Emerging Concepts in the Medical and Surgical Treatment of Obesity. <i>Frontiers of Hormone Research</i> , 2008, 36, 229-259.	1.0	36
193	Applying the Chronic Care Model to the Management of Obesity. <i>Obesity Management</i> , 2008, 4, 227-231.	0.2	5
194	Consensus on infertility treatment related to polycystic ovary syndrome. <i>Human Reproduction</i> , 2008, 23, 462-477.	0.4	499
195	Maintaining large weight losses: The role of behavioral and psychological factors.. <i>Journal of Consulting and Clinical Psychology</i> , 2008, 76, 1015-1021.	1.6	145
196	Medical Management of Obesity. <i>Current Nutrition and Food Science</i> , 2008, 4, 145-153.	0.3	1
198	Obesity and Reproduction. <i>Postgraduate Obstetrics &amp; Gynecology</i> , 2008, 28, 1-6.	0.1	1
199	Obesity and Reproduction. <i>Postgraduate Obstetrics &amp; Gynecology</i> , 2008, 28, 8.	0.1	0
200	Treatment for polycystic ovary syndrome: a critical appraisal of treatment options. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 349-359.	1.2	4
202	Adherence to a behavioral weight loss treatment program enhances weight loss and improvements in biomarkers. <i>Patient Preference and Adherence</i> , 2009, 3, 151.	0.8	104
203	The use of sibutramine in the management of obesity and related disorders: An update. <i>Vascular Health and Risk Management</i> , 2009, 5, 441.	1.0	57
204	Effectiveness of a Multidisciplinary Program for Management of Obesity: The Unit�� d��Enseignement, de Traitement et de Recherche sur lâ€™Ob��sit�� (UETRO) Database Study. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 297-304.	0.5	13
205	Comparing of feedback-collection and think-aloud methods in program comprehension studies. <i>Behaviour and Information Technology</i> , 2009, 28, 139-164.	2.5	19

#	ARTICLE	IF	CITATIONS
206	Improving Weight Management in Primary Care Practice: A Possible Role for Auxiliary Health Professionals Collaborating with Primary Care Physicians. <i>Obesity and Weight Management</i> , 2009, 5, 210-215.	0.1	7
207	Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults. <i>Medicine and Science in Sports and Exercise</i> , 2009, 41, 459-471.	0.2	1,894
208	Current and Future Drugs for Appetite Regulation and Obesity Treatment. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2009, 3, 102-128.	0.7	3
210	Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. <i>Endoscopy</i> , 2009, 41, 575-580.	1.0	109
212	Experiences of Self-Monitoring: Successes and Struggles During Treatment for Weight Loss. <i>Qualitative Health Research</i> , 2009, 19, 815-828.	1.0	128
213	Cardiovascular Evaluation and Management of Severely Obese Patients Undergoing Surgery. <i>Circulation</i> , 2009, 120, 86-95.	1.6	255
214	Management of Atypical Antipsychotic Drug-Induced Weight Gain: Focus on Metformin. <i>Pharmacotherapy</i> , 2009, 29, 725-735.	1.2	31
215	Position of the American Dietetic Association: Weight Management. <i>Journal of the American Dietetic Association</i> , 2009, 109, 330-346.	1.3	255
216	Psychological Variables Associated with Weight Loss in Obese Patients Seeking Treatment at Medical Centers. <i>Journal of the American Dietetic Association</i> , 2009, 109, 2010-2016.	1.3	70
217	Obesity as a disease state: A new paradigm for diagnosis and treatment. <i>Clinical Cornerstone</i> , 2009, 9, 9-29.	1.0	70
218	Treating diabetes and prediabetes by focusing on obesity management. <i>Current Diabetes Reports</i> , 2009, 9, 348-354.	1.7	44
219	Treatment of Obesity in Primary Care Practice in the United States: A Systematic Review. <i>Journal of General Internal Medicine</i> , 2009, 24, 1073-1079.	1.3	190
220	Pharmacotherapy for obesity. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 804-810.	1.1	79
221	Motivation, Readiness to Change, and Weight Loss Following Adjustable Gastric Band Surgery. <i>Obesity</i> , 2009, 17, 698-705.	1.5	77
222	Greater Omentectomy Improves Insulin Sensitivity in Nonobese Dogs. <i>Obesity</i> , 2009, 17, 674-680.	1.5	43
223	Changes in Symptoms of Depression With Weight Loss: Results of a Randomized Trial. <i>Obesity</i> , 2009, 17, 1009-1016.	1.5	77
224	Adult weight management: Translating research and guidelines into practice. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 197-206.	1.4	22
225	Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. <i>Obesity Reviews</i> , 2009, 10, 333-341.	3.1	72

#	ARTICLE	IF	CITATIONS
226	Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. <i>Obesity Reviews</i> , 2009, 10, 564-575.	3.1	75
227	MORE PRO-ACTIVITY IS REQUIRED IN THE BATTLE AGAINST OBESITY IN MEN. <i>BJU International</i> , 2009, 103, 1019-1020.	1.3	2
228	Obesity Management Interventions: A Review of the Evidence. <i>Population Health Management</i> , 2009, 12, 305-316.	0.8	16
229	Adherence and weight loss outcomes associated with food-exercise diary preference in a military weight management program. <i>Eating Behaviors</i> , 2009, 10, 220-227.	1.1	56
230	Predictors of attrition and weight loss success: Results from a randomized controlled trial. <i>Behaviour Research and Therapy</i> , 2009, 47, 685-691.	1.6	133
231	SMART trial: A randomized clinical trial of self-monitoring in behavioral weight management-design and baseline findings. <i>Contemporary Clinical Trials</i> , 2009, 30, 540-551.	0.8	109
232	Physical training combined with dietary measures in the treatment of adult obesity. A comparison of two protocols. <i>Annals of Physical and Rehabilitation Medicine</i> , 2009, 52, 394-413.	1.1	34
233	Medical students' self-perceived competence and prescription of patient-centered physical activity. <i>Preventive Medicine</i> , 2009, 48, 164-166.	1.6	29
242	Introduction. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	0
243	Obesity: Why be Concerned?. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	135
244	Regulation of Energy Homeostasis and Health Consequences in Obesity. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	45
245	Obesity Prevention: Recommended Strategies and Challenges. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	13
246	When Prevention Fails: Obesity Treatment Strategies. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	31
247	An Obesity/Cardiometabolic Risk Reduction Disease Management Program: A Population-Based Approach. <i>American Journal of Medicine</i> , 2009, 122, I-CO4.	0.6	4
248	Acute tryptophan depletion and sweet food consumption by overweight adults. <i>Eating Behaviors</i> , 2009, 10, 36-41.	1.1	18
250	Managing Obesity: General Approach and Lifestyle Intervention. , 0, , 393-417.		0
251	Medications for Obesity: Mechanisms and Applications. <i>Clinics in Chest Medicine</i> , 2009, 30, 525-538.	0.8	23
253	Obesity and Its Relationship to Infertility in Men and Women. <i>Obstetrics and Gynecology Clinics of North America</i> , 2009, 36, 333-346.	0.7	54

#	ARTICLE	IF	CITATIONS
254	Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy. American Journal of Therapeutics, 2009, 16, 354-364.	0.5	60
255	Behavior therapy for obesity: where are we now?. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 347-352.	1.2	98
256	Comparison of Methods for Delivering a Lifestyle Modification Program for Obese Patients. Annals of Internal Medicine, 2009, 150, 255.	2.0	134
258	Trial of Family and Friend Support for Weight Loss in African American Adults. Archives of Internal Medicine, 2009, 169, 1795-804.	4.3	105
260	Visceral Adipose Tissue and Atherosclerosis. Current Vascular Pharmacology, 2009, 7, 169-179.	0.8	60
261	Targeting MCP-1 to Reduce Vascular Complications of Obesity. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 164-176.	1.5	14
262	Treating Obesity in Chronic Kidney Disease. Nutrition Today, 2009, 44, 118-123.	0.6	0
263	Treatment of Obesity With "Combination" Pharmacotherapy. American Journal of Therapeutics, 2010, 17, 596-603.	0.5	25
264	European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?. Journal of Hypertension, 2010, 28, 637-643.	0.3	39
268	Medical Therapy for Obesity. Mount Sinai Journal of Medicine, 2010, 77, 407-417.	1.9	19
269	Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults. Circulation, 2010, 122, 406-441.	1.6	760
270	The Association Between Rate of Initial Weight Loss and Long-Term Success in Obesity Treatment: Does Slow and Steady Win the Race?. International Journal of Behavioral Medicine, 2010, 17, 161-167.	0.8	128
271	Therapeutic Approaches to Obesity. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 381-395.	0.4	31
272	Assessment of the Application of the Intra-gastric Balloon Together with Sibutramine: A Prospective Clinical Study. Obesity Surgery, 2010, 20, 1117-1120.	1.1	11
273	Sympathetic nervous activation in obesity and the metabolic syndrome"Causes, consequences and therapeutic implications. , 2010, 126, 159-172.		267
274	Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health, 2010, 10, 653.	1.2	122
275	The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. European Journal of Pharmacology, 2010, 636, 88-95.	1.7	31
276	Bariatric surgery: A primer for eating disorder professionals. European Eating Disorders Review, 2010, 18, 304-317.	2.3	13

#	ARTICLE	IF	CITATIONS
277	Eating disorders, obesity and addiction. <i>European Eating Disorders Review</i> , 2010, 18, 341-351.	2.3	132
278	New psycho-pedagogic approach to obesity treatment: A 5-year follow-up. <i>Patient Education and Counseling</i> , 2010, 79, 333-337.	1.0	21
279	Group motivational intervention in overweight/obese patients in primary prevention of cardiovascular disease in the primary healthcare area. <i>BMC Family Practice</i> , 2010, 11, 23.	2.9	9
280	Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial. <i>BMC Psychiatry</i> , 2010, 10, 108.	1.1	34
281	Weight loss in individuals with metabolic syndrome given DASH diet counseling when provided a low sodium vegetable juice: a randomized controlled trial. <i>Nutrition Journal</i> , 2010, 9, 8.	1.5	34
282	Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. <i>International Journal of Clinical Practice</i> , 2010, 64, 544-557.	0.8	10
283	Erectile dysfunction and hormonal imbalance in morbidly obese male is reversed after gastric bypass surgery: a prospective randomized controlled trial. <i>Journal of Developmental and Physical Disabilities</i> , 2010, 33, 736-744.	3.6	132
284	Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period. <i>Obesity</i> , 2010, 18, 987-994.	1.5	17
285	Effects of a Low-intensity Intervention That Prescribed a Low-carbohydrate vs. a Low-fat Diet in Obese, Diabetic Participants. <i>Obesity</i> , 2010, 18, 1733-1738.	1.5	118
286	A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet. <i>Obesity</i> , 2010, 18, 2301-2310.	1.5	24
287	Proof-of-concept trial on the efficacy of sodium tungstate in human obesity. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1013-1018.	2.2	26
288	Variegate porphyria in a 46-year-old patient taking sibutramine for weight loss. <i>Obesity Reviews</i> , 2010, 11, 329-331.	3.1	3
289	Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. <i>Obesity Reviews</i> , 2010, 11, 777-791.	3.1	31
290	Lorcaserin for the treatment of obesity. <i>Drugs of Today</i> , 2010, 46, 901.	0.7	22
291	Pre-operative management: Nutritionist/psychologist/internist. , 0, , 79-84.		1
292	“Can We Talk About Your Weight for a Few Minutes, Mr. Jones?” <i>AMA Journal of Ethics</i> , 2010, 12, 299-304.	0.4	2
294	Ovulation induction for anovulatory patients. , 0, , 14-26.		0
295	Tackling obesity: new therapeutic agents for assisted weight loss. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, Volume 3, 95-112.	1.1	12



#	ARTICLE	IF	CITATIONS
296	Maintenance of Weight Loss in Adolescents: Current Status and Future Directions. <i>Journal of Obesity</i> , 2010, 2010, 1-12.	1.1	32
297	Effects of Native Banana Starch Supplementation on Body Weight and Insulin Sensitivity in Obese Type 2 Diabetics. <i>International Journal of Environmental Research and Public Health</i> , 2010, 7, 1953-1962.	1.2	51
298	Obesity and Preclinical Changes of Cardiac Geometry and Function. <i>Korean Circulation Journal</i> , 2010, 40, 55.	0.7	16
299	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 263-273.	1.1	13
300	Clinical and economic considerations of antiobesity treatment: a review of orlistat. <i>ClinicoEconomics and Outcomes Research</i> , 2010, 2, 63.	0.7	15
301	Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010, 13, 378.	0.9	11
302	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 3, 373-385.	1.1	54
303	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. <i>Annals of Medicine</i> , 2010, 42, 19-35.	1.5	23
304	Exercise Prescription and Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2010, 121, 2601-2604.	1.6	61
305	Impact of Obesity on Gynecology. <i>Women's Health</i> , 2010, 6, 107-117.	0.7	49
306	Independent but coordinated trials: insights from the Practice-based Opportunities for Weight Reduction Trials Collaborative Research Group. <i>Clinical Trials</i> , 2010, 7, 322-332.	0.7	28
308	The Role of Internet Technology in Enhancing the Effectiveness of Lifestyle Interventions for Weight Management. <i>Obesity and Weight Management</i> , 2010, 6, 131-135.	0.1	0
309	Behavioral and pharmacologic therapies for obesity. <i>Nature Reviews Endocrinology</i> , 2010, 6, 578-588.	4.3	98
310	Overweight in older children and adolescents: treatment or prevention?. <i>Archives of Disease in Childhood</i> , 2010, 95, 1-2.	1.0	3
311	A low intensity, community based lifestyle programme to prevent weight gain in women with young children: cluster randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c3215-c3215.	2.4	89
312	Pharmacotherapy for Obesity. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2010, 4, 47-58.	0.7	3
313	Pharmacologic Therapies for Obesity. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 69-79.	1.0	69
315	Prevention and treatment of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 331-340.	0.4	18



#	ARTICLE	IF	CITATIONS
316	A telephonic coaching program has more impact when body mass index is over 35. <i>Obesity Research and Clinical Practice</i> , 2010, 4, e65-e72.	0.8	4
317	Effect of a worksite-based intervention program on metabolic parameters in middle-aged male white-collar workers: A randomized controlled trial. <i>Preventive Medicine</i> , 2010, 51, 11-17.	1.6	65
318	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2657-2672.	0.9	20
319	Behavioral Treatment of Obesity. <i>Psychiatric Clinics of North America</i> , 2011, 34, 841-859.	0.7	368
320	Medical Therapy for Obesity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 203-212.	0.6	1
321	Cognitive and Behavioral Approaches in the Treatment of Obesity. <i>Medical Clinics of North America</i> , 2011, 95, 971-988.	1.1	50
322	TRAMOMTANA (Multidisciplinary treatment of morbid obesity: Medication, behavioral therapy,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50 clinical trial (II). <i>EndocrinologÃa Y NutriciÃn (English Edition)</i> , 2011, 58, 299-307.	0.5	5
323	Binge Eating Disorder and the Outcome of Bariatric Surgery at One Year: A Prospective, Observational Study. <i>Obesity</i> , 2011, 19, 1220-1228.	1.5	102
325	Medications for Weight Reduction. <i>Medical Clinics of North America</i> , 2011, 95, 989-1008.	1.1	8
326	A Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice. <i>New England Journal of Medicine</i> , 2011, 365, 1969-1979.	13.9	434
327	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
328	The 5-HT6 Receptor as a Target for Developing Novel Antiobesity Drugs. <i>International Review of Neurobiology</i> , 2011, 96, 73-109.	0.9	24
329	Dietary intake and eating behavior after bariatric surgery: threats to weight loss maintenance and strategies for success. <i>Surgery for Obesity and Related Diseases</i> , 2011, 7, 644-651.	1.0	182
330	Does medically induced weight loss improve obstructive sleep apnoea in the obese: review of randomized trials. <i>Clinical Obesity</i> , 2011, 1, 26-30.	1.1	4
331	VLED and formula LED in the management of type 2 diabetes: defining the clinical need and research requirements. <i>Clinical Obesity</i> , 2011, 1, 41-49.	1.1	11
333	Present and Future: Pharmacologic Treatment of Obesity. <i>Journal of Obesity</i> , 2011, 2011, 1-13.	1.1	43
334	Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine. <i>Journal of Obesity</i> , 2011, 2011, 1-8.	1.1	2
335	Behavioral Treatment of Obesity. , 2011, , .		2

#	ARTICLE	IF	CITATIONS
336	European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. <i>Journal of Hypertension</i> , 2011, 29, 189-193.	0.3	11
337	Is there a path for approval of an antiobesity drug. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011, 18, 321-327.	1.2	9
338	Pharmacotherapy for overweight/obesity in ethnic minorities and White Caucasians: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 385-393.	2.2	16
339	Behavioural weight management for the primary careprovider. <i>Obesity Reviews</i> , 2011, 12, e290-7.	3.1	15
340	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 592-601.	0.7	11
341	Treatment Strategies for Overweight and Obesity. <i>Journal of Nursing Scholarship</i> , 2011, 43, 368-375.	1.1	40
342	Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The CORâ€œBMOD Trial. <i>Obesity</i> , 2011, 19, 110-120.	1.5	394
343	The Effect of Electronic Selfâ€œMonitoring on Weight Loss and Dietary Intake: A Randomized Behavioral Weight Loss Trial. <i>Obesity</i> , 2011, 19, 338-344.	1.5	290
344	Relationship between diet, exercise habits, and health status among patients with diabetes. <i>Research in Social and Administrative Pharmacy</i> , 2011, 7, 151-161.	1.5	14
345	Self-Monitoring in Weight Loss: A Systematic Review of the Literature. <i>Journal of the American Dietetic Association</i> , 2011, 111, 92-102.	1.3	1,016
346	Using a Personal Digital Assistant for Self-Monitoring Influences Diet Quality in Comparison to a Standard Paper Record among Overweight/Obese Adults. <i>Journal of the American Dietetic Association</i> , 2011, 111, 583-588.	1.3	83
347	Obesity management: lifestyle modification, diet and surgery. <i>Trends in Urology &amp; Men's Health</i> , 2011, 2, 8-11.	0.2	0
348	Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain. <i>International Journal of Clinical Pharmacy</i> , 2011, 33, 627-633.	1.0	8
349	The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 941-947.	0.8	1
350	Determinants of Increased Cardiovascular Disease in Obesity and Metabolic Syndrome. <i>Current Medicinal Chemistry</i> , 2011, 18, 5267-5280.	1.2	55
351	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 121-136.	1.0	18
352	The Metabolic Syndrome. , 2011, , 13-39.		2
353	Hyperlipidemia in Primary Care. , 2011, , .		2

#	ARTICLE	IF	CITATIONS
354	Behavioral therapy for management of obesity. Indian Journal of Endocrinology and Metabolism, 2012, 16, 28.	0.2	37
355	Lifestyle Modification for Obesity. Circulation, 2012, 125, 1157-1170.	1.6	461
356	Evaluating Parents and Adult Caregivers as "Agents of Change" for Treating Obese Children: Evidence for Parent Behavior Change Strategies and Research Gaps. Circulation, 2012, 125, 1186-1207.	1.6	211
357	Reducing The Impact Of Diabetes: Is Prevention Feasible Today, Or Should We Aim For Better Treatment?. Health Affairs, 2012, 31, 76-83.	2.5	9
358	Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. International Journal of Obesity, 2012, 36, 1522-1528.	1.6	64
359	Conservative Treatment of Overweight and Obesity. , 2012, , 13-20.		0
360	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. Journal of Hypertension, 2012, 30, 1047-1055.	0.3	134
361	A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults. Sleep, 2012, 35, 1529-1539.	0.6	117
362	Weight Loss and Metabolic Improvement in Morbidly Obese Subjects Implanted for 1 Year With an Endoscopic Duodenal-jejunal Bypass Liner. Annals of Surgery, 2012, 255, 1080-1085.	2.1	103
363	One-Year Changes in Symptoms of Depression and Weight in Overweight/Obese Individuals With Type 2 Diabetes in the Look AHEAD Study. Obesity, 2012, 20, 783-793.	1.5	94
364	Intensity and Duration of Obesity-Related Counseling: Association With 5-Year BMI Trends Among Obese Primary Care Patients. Obesity, 2012, 20, 773-782.	1.5	17
365	Do we need anti-obesity drugs?. Diabetes/Metabolism Research and Reviews, 2012, 28, 8-20.	1.7	32
366	Self-Monitoring and Eating-Related Behaviors Are Associated with 12-Month Weight Loss in Postmenopausal Overweight-to-Obese Women. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 1428-1435.	0.4	47
367	Obesity in Polycystic Ovary Syndrome: Insulin Sensitizing Therapy. Current Obesity Reports, 2012, 1, 191-198.	3.5	2
368	Diabetes obesity link: how to lower your risk of diabetes with weight management. Osteopathic Family Physician, 2012, 4, 149-154.	0.2	0
369	Exercise, appetite and weight management: understanding the compensatory responses in eating behaviour and how they contribute to variability in exercise-induced weight loss. British Journal of Sports Medicine, 2012, 46, 315-322.	3.1	131
370	Adoption of diet-related self-monitoring behaviors varies by race/ethnicity, education, and baseline binge eating score among overweight-to-obese postmenopausal women in a 12-month dietary weight loss intervention. Nutrition Research, 2012, 32, 260-265.	1.3	15
371	Using mHealth Technology to Enhance Self-Monitoring for Weight Loss. American Journal of Preventive Medicine, 2012, 43, 20-26.	1.6	269

#	ARTICLE	IF	CITATIONS
372	Outcomes from a Medical Weight Loss Program: Primary Care Clinics Versus Weight Loss Clinics. <i>American Journal of Medicine</i> , 2012, 125, 603.e7-603.e11.	0.6	14
373	Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007â€“2008. <i>Annals of Epidemiology</i> , 2012, 22, 349-353.	0.9	43
374	The <sc>CHANGE</sc> Program: Comparing an Interactive versus Prescriptive Obesity Intervention on University Students' Selfâ€Esteem and Quality of Life. <i>Applied Psychology: Health and Well-Being</i> , 2012, 4, 369-389.	1.6	9
375	Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1492-1526.	2.5	247
376	Obesity Therapy. , 2012, , 313-337.		0
377	A Randomized Pilot Trial of a Full Subsidy vs. a Partial Subsidy for Obesity Treatment. <i>Obesity</i> , 2012, 20, 1838-1843.	1.5	6
378	Obesity and Weight Loss in the Treatment and Prevention of Osteoarthritis. <i>PM and R</i> , 2012, 4, S59-67.	0.9	152
380	Short-Term Effects of Sibutramine on Mineral Status and Selected Biochemical Parameters in Obese Women. <i>Biological Trace Element Research</i> , 2012, 149, 163-170.	1.9	4
381	The Role of Obesity in Cancer Survival and Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1244-1259.	1.1	248
382	Defining the role of bariatric surgery in polycystic ovarian syndrome patients. <i>World Journal of Diabetes</i> , 2012, 3, 71.	1.3	35
383	Weight Loss Is Still an Essential Intervention in Obesity and its Complications: A Review. <i>Journal of Obesity</i> , 2012, 2012, 1-6.	1.1	8
385	Impact of health legislation on the sale of anorectics in a city in the Amazon region. <i>Acta Amazonica</i> , 2012, 42, 215-220.	0.3	2
386	The Effect of Weight Loss in Obesity and Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2012, 14, 170-176.	1.5	30
387	Technology Interventions to Curb Obesity: A Systematic Review of the Current Literature. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 120-134.	0.8	93
388	An Acceptance-Based Behavioral Intervention for Weight Loss: A Pilot Study. <i>Behavior Therapy</i> , 2012, 43, 427-435.	1.3	89
389	Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease. <i>BMC Research Notes</i> , 2012, 5, 126.	0.6	4
390	Self-Monitoring as a Mediator of Weight Loss in the SMART Randomized Clinical Trial. <i>International Journal of Behavioral Medicine</i> , 2013, 20, 556-561.	0.8	63
391	The effect of orlistat on body weight in obese Czech adults. <i>Open Medicine (Poland)</i> , 2013, 8, 553-557.	0.6	0

#	ARTICLE	IF	CITATIONS
392	Obesity. <i>Annals of Internal Medicine</i> , 2013, 159, ITC3.	2.0	53
393	Ubiquitous monitoring and assessment of childhood obesity. <i>Personal and Ubiquitous Computing</i> , 2013, 17, 1147-1157.	1.9	7
394	Mobile Applications for Weight Management. <i>American Journal of Preventive Medicine</i> , 2013, 45, 583-589.	1.6	319
395	Interface between Pharmacotherapy and Genes in Human Obesity. <i>Human Heredity</i> , 2013, 75, 116-126.	0.4	8
396	Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial. <i>International Journal of Obesity</i> , 2013, 37, S19-S24.	1.6	38
397	Brief Interventions for Weight Loss in Primary Care. <i>Current Obesity Reports</i> , 2013, 2, 341-347.	3.5	5
398	Body weight reduction and metformin: Roles in polycystic ovary syndrome. <i>Pathophysiology</i> , 2013, 20, 131-137.	1.0	13
399	Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. <i>Obesity</i> , 2013, 21, 2163-2171.	1.5	185
400	Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 741-756.	1.0	24
401	Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. <i>International Journal of Obesity</i> , 2013, 37, 1443-1451.	1.6	562
402	Pharmacotherapy for childhood obesity: present and future prospects. <i>International Journal of Obesity</i> , 2013, 37, 1-15.	1.6	63
403	Aspiration Therapy Leads to Weight Loss in Obese Subjects: A Pilot Study. <i>Gastroenterology</i> , 2013, 145, 1245-1252.e5.	0.6	145
404	Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and the Obesity Society. <i>Endocrine Practice</i> , 2013, 19, 1-82.	1.1	90
405	Effect of source of funding on weight loss up to 3 years after gastric banding. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 1219-1224.	1.3	5
406	Treatment of Adolescent Obesity Comparing Self-Guided and Group Lifestyle Modification Programs: A Potential Model for Primary Care. <i>Journal of Pediatric Psychology</i> , 2013, 38, 978-986.	1.1	32
407	Lifestyle modification in the management of obesity: achievements and challenges. <i>Eating and Weight Disorders</i> , 2013, 18, 339-349.	1.2	36
408	Adherence and Weight Loss Outcomes in Bariatric Surgery: Does Cognitive Function Play a Role?. <i>Obesity Surgery</i> , 2013, 23, 1703-1710.	1.1	56
409	Diet Quality. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
410	Predictors of Successful Weight Loss. American Journal of Lifestyle Medicine, 2013, 7, 115-117.	0.8	2
411	Managing obesity in primary care practice: a narrative review. Annals of the New York Academy of Sciences, 2013, 1281, 191-206.	1.8	85
412	Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: A randomized trial. Obesity, 2013, 21, 2481-2487.	1.5	16
413	Musculoskeletal function following bariatric surgery. Obesity, 2013, 21, 1104-1110.	1.5	20
414	Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. International Journal of Obesity, 2013, 37, S3-S11.	1.6	58
415	Changes in eating, physical activity and related behaviors in a primary care-based weight loss intervention. International Journal of Obesity, 2013, 37, S12-S18.	1.6	21
416	Thermogenesis-based interventions for obesity and Type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2013, 8, 275-288.	1.2	4
417	Randomized controlled trial of a comprehensive home environment-focused weight-loss program for adults.. Health Psychology, 2013, 32, 128-137.	1.3	94
418	Patterns of success: Online self-monitoring in a web-based behavioral weight control program.. Health Psychology, 2013, 32, 164-170.	1.3	78
419	The role of sibutramine in weight reduction. Bratislava Medical Journal, 2013, 114, 155-157.	0.4	2
420	Benefits and risks of weight-loss treatment for older, obese women. Clinical Interventions in Aging, 2013, 8, 157.	1.3	3
421	Effects of Lifestyle Modification on Pregnancy Success in Obese and Overweight Women with PCOS. Journal of Women's Health Care, 2013, 02, .	0.2	0
424	Anti-Obesity Drugs for Obese Women Planning Pregnancy. , 2013, , 423-430.		1
425	Knowing What's Out There: Awareness of Non-Alcoholic Fatty Liver Disease. Frontiers in Medicine, 2014, 1, 4.	1.2	76
426	Effect of a 12-week weight management program on the clinical characteristics and dietary intake of the young obese and the contributing factors to the successful weight loss. Nutrition Research and Practice, 2014, 8, 571.	0.7	1
427	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opinion on Pharmacotherapy, 2014, 15, 809-822.	0.9	23
428	Obesity Management: Applying Clinical Trial Data to Clinical Care. Endocrine Practice, 2014, 20, 6-19.	1.1	2
429	Intraduodenal milk protein concentrate augments the glycemic and food intake suppressive effects of DPP-IV inhibition. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 306, R157-R163.	0.9	11

#	ARTICLE	IF	CITATIONS
430	Effectiveness of a Smartphone Application for Weight Loss Compared With Usual Care in Overweight Primary Care Patients. <i>Annals of Internal Medicine</i> , 2014, 161, S5.	2.0	304
431	Readiness redefined: A behavioral task during screening predicted 1-year weight loss in the look AHEAD study. <i>Obesity</i> , 2014, 22, 1016-1023.	1.5	20
432	Incidence of Conversion to Active Waitlist Status Among Temporarily Inactive Obese Renal Transplant Candidates. <i>Transplantation</i> , 2014, 98, 177-186.	0.5	31
433	Randomized Pilot Trial of Bariatric Surgery Versus Intensive Medical Weight Management on Diabetes Remission in Type 2 Diabetic Patients Who Do NOT Meet NIH Criteria for Surgery and the Role of Soluble RAGE as a Novel Biomarker of Success. <i>Annals of Surgery</i> , 2014, 260, 617-624.	2.1	100
434	Dietary restriction reverses obesity-induced anhedonia. <i>Physiology and Behavior</i> , 2014, 128, 126-132.	1.0	23
435	The Role of Medications for the Management of Patients with NAFLD. <i>Clinics in Liver Disease</i> , 2014, 18, 73-89.	1.0	27
436	Developing self-management education in coronary artery disease. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 133-139.	0.8	23
437	Collective Efficacy and Obesity-Related Health Behaviors in a Community Sample of African Americans. <i>Journal of Community Health</i> , 2014, 39, 124-131.	1.9	37
438	Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2786-2788.	1.2	9
439	Long-term Drug Treatment for Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 74.	3.8	697
440	Tolerability and Safety of the New Anti-Obesity Medications. <i>Drug Safety</i> , 2014, 37, 693-702.	1.4	69
441	Lifestyle Management for Enhancing Outcomes after Bariatric Surgery. <i>Current Diabetes Reports</i> , 2014, 14, 540.	1.7	25
442	Treatment of the Obese Patient. , 2014, , .		3
443	Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: Randomized placebo-controlled clinical trial of self-help and medication. <i>Behaviour Research and Therapy</i> , 2014, 58, 1-9.	1.6	59
444	Definition of intervention points in prediabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 667-675.	5.5	52
445	Obesity treatment in disadvantaged population groups: Where do we stand and what can we do?. <i>Preventive Medicine</i> , 2014, 68, 71-75.	1.6	41
446	Optimization of remotely delivered intensive lifestyle treatment for obesity using the Multiphase Optimization Strategy: Opt-IN study protocol. <i>Contemporary Clinical Trials</i> , 2014, 38, 251-259.	0.8	72
447	Behavioral Approaches to the Treatment of Obesity. , 2014, , 149-162.		1



#	ARTICLE	IF	CITATIONS
448	Comparative effectiveness of three doses of weight-loss counseling: Two-year findings from the rural LITE trial. <i>Obesity</i> , 2014, 22, 2293-2300.	1.5	49
449	Factors predictive of drop-out and weight loss success in weight management of obese patients. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 24-32.	1.3	73
450	Obesity at Menopause: An Expanding Problem. <i>Journal of Patient Care</i> , 2015, 01, .	0.1	15
451	Advances in the Endoscopic Management of Obesity. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	0.7	20
452	Long-Term Weight Maintenance after a 17-Week Weight Loss Intervention with or without a One-Year Maintenance Program: A Randomized Controlled Trial. <i>Journal of Obesity</i> , 2015, 2015, 1-10.	1.1	32
454	Disruption of KATP Channel Expression in Skeletal Muscle by Targeted Oligonucleotide Delivery Promotes Activity-linked Thermogenesis. <i>Molecular Therapy</i> , 2015, 23, 707-716.	3.7	8
455	Obesity in the US: what is the best role for primary care?. <i>BMJ, The</i> , 2015, 350, g7846-g7846.	3.0	27
456	Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. <i>Lancet Diabetes and Endocrinology,the</i> , 2015, 3, 232-234.	5.5	85
457	Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 342-362.	1.8	891
458	Weight Loss for a Healthy Liver. <i>Gastroenterology</i> , 2015, 149, 274-278.	0.6	11
459	Does cognitive behavioral therapy strengthen the effect of bariatric surgery for obesity? Design and methods of a randomized and controlled study. <i>Contemporary Clinical Trials</i> , 2015, 42, 252-256.	0.8	15
460	Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. <i>Diabetes</i> , 2015, 64, 2299-2309.	0.3	41
461	Piloting a New Approach to the Treatment of Obesity Using Dexamphetamine. <i>Frontiers in Endocrinology</i> , 2015, 6, 14.	1.5	10
462	Technology-based interventions in the treatment of overweight and obesity: A systematic review. <i>Appetite</i> , 2015, 95, 138-151.	1.8	107
463	When it comes to lifestyle recommendations, more is sometimes less: A meta-analysis of theoretical assumptions underlying the effectiveness of interventions promoting multiple behavior domain change.. <i>Psychological Bulletin</i> , 2015, 141, 474-509.	5.5	90
464	Combination phentermine and topiramate extended release in the management of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1263-1274.	0.9	24
465	The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987-2011. <i>Pharmacoeconomics</i> , 2015, 33, 691-697.	1.7	12
466	Diagnostic criteria for osteoporosis should be expanded. <i>Lancet Diabetes and Endocrinology,the</i> , 2015, 3, 234-236.	5.5	5



#	ARTICLE	IF	CITATIONS
467	Interventions of Weight Reduction and Prevention in Children and Adolescents. American Journal of Therapeutics, 2015, 22, 159-166.	0.5	0
468	Diet, Exercise, and Behavior Therapy in the Treatment of Obesity and Metabolic Syndrome. , 2015, , 1-14.		0
469	Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4048-4058.	1.8	180
470	A Shared Molecular and Genetic Basis for Food and Drug Addiction. Psychiatric Clinics of North America, 2015, 38, 419-462.	0.7	23
471	Exploratory and Confirmatory Factor Analyses and Demographic Correlate Models of the Strategies for Weight Management Measure for Overweight or Obese Adults. American Journal of Health Promotion, 2015, 29, e147-e157.	0.9	7
472	Multidisciplinary Approach to Obesity. , 2015, , .		8
473	GLP-1 Plays a Limited Role in Improved Glycemia Shortly After Roux-en-Y Gastric Bypass: A Comparison With Intensive Lifestyle Modification. Diabetes, 2015, 64, 434-446.	0.3	63
476	<a href="http://www.omicsgroup.org/journals/effects-of-borax-and-sleeve-gastrectomy-on-mrna-expression-of-antioxidant-genes-in-substantia-nigra">http://www.omicsgroup.org/journals/effects-of-borax-and-sleeve-gastrectomy-on-mrna-expression-of-antioxidant-genes-in-substantia-nigra</a> Journal of Obesity & Weight Loss Therapy, 2016, 06, .	0.1	2
478	American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice, 2016, 22, 1-203.	1.1	952
479	Management of Obesity. Journal of Clinical Oncology, 2016, 34, 4295-4305.	0.8	50
480	Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team. Obesity Science and Practice, 2016, 2, 256-265.	1.0	10
481	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. Current Atherosclerosis Reports, 2016, 18, 36.	2.0	13
482	Endoscopic Devices for Obesity. Current Obesity Reports, 2016, 5, 251-261.	3.5	12
484	Weight loss maintenance strategies among rural breast cancer survivors: The rural women connecting for better health trial. Obesity, 2016, 24, 2070-2077.	1.5	40
485	Advancing the revolution in the behavioral treatment of obesity. Obesity, 2016, 24, 2029-2030.	1.5	4
486	An update on naltrexone/bupropion extended-release in the treatment of obesity. Expert Opinion on Pharmacotherapy, 2016, 17, 2235-2242.	0.9	10
487	Cut-off values of blood mercury concentration in relation to increased body mass index and waist circumference in Koreans. Journal of Investigative Medicine, 2016, 64, 867-871.	0.7	9
488	Behavioral Treatment of the Patient with Obesity. Endocrinology and Metabolism Clinics of North America, 2016, 45, 565-580.	1.2	28

#	ARTICLE	IF	CITATIONS
489	Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. <i>Clinical Obesity</i> , 2016, 6, 233-242.	1.1	22
490	GLP-1 analogue use in patients with sub-optimally controlled type 1 diabetes or obesity improves weight and HbA <sub>1c</sub> . <i>Practical Diabetes</i> , 2016, 33, 13-17.	0.1	3
491	Current practices of obesity pharmacotherapy, bariatric surgery referral and coding for counselling by healthcare professionals. <i>Obesity Science and Practice</i> , 2016, 2, 266-271.	1.0	32
492	The ABCDs of Lifestyle Counseling. <i>JAMA Cardiology</i> , 2016, 1, 505.	3.0	16
493	A randomized controlled trial testing an Internet delivered cost-effective benefit approach to weight loss maintenance. <i>Preventive Medicine</i> , 2016, 92, 51-57.	1.6	31
495	Bile acids synthesis decreases after laparoscopic sleeve gastrectomy. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 763-769.	1.0	25
496	Random control trial of hot compresses for women those who used laxatives on severity of constipation and quality of life. <i>Japan Journal of Nursing Science</i> , 2016, 13, 95-104.	0.5	3
497	A systematic review and meta-analysis of primary prevention programmes to improve cardio-metabolic risk in non-urban communities. <i>Preventive Medicine</i> , 2016, 87, 22-34.	1.6	26
498	Albert J. Stunkard: His Research on Obesity and Its Psychological Impact. <i>Current Obesity Reports</i> , 2016, 5, 140-144.	3.5	0
499	Eating Behaviors and Weight Development in Obesity-Prone Children and the Importance of the Research of Albert J. Stunkard. <i>Current Obesity Reports</i> , 2016, 5, 126-131.	3.5	3
500	Diet, Exercise, and Behavior Therapy in the Treatment of Obesity and Metabolic Syndrome. , 2016, , 783-795.		0
501	Supportive Cancer Care. , 2016, , .		1
502	Protocol for the Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER) Trial: Comparing three obesity treatment models in rural primary care. <i>Contemporary Clinical Trials</i> , 2016, 47, 304-314.	0.8	22
503	Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 655-659.	1.5	10
504	Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 164-174.	1.3	8
505	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 52-63.	1.0	4
506	Endoscopic bariatric procedures: Assessment of postintervention safety and success. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 46-51.	0.3	0
507	Association between weight bias internalization and metabolic syndrome among treatment-seeking individuals with obesity. <i>Obesity</i> , 2017, 25, 317-322.	1.5	110

#	ARTICLE	IF	CITATIONS
508	Maintenance of Weight Loss After Initiation of Nutrition Training. <i>Annals of Internal Medicine</i> , 2017, 166, 463.	2.0	45
509	Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results. <i>Gastroenterology</i> , 2017, 152, 1752-1764.	0.6	111
510	A "Backward" Bayesian Method for Determination of Criteria for Making Go/No-Go Decisions in the Early Phases. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 153-159.	0.6	2
511	Daily supplementation of dietary protein improves the metabolic effects of GLP-1-based pharmacotherapy in lean and obese rats. <i>Physiology and Behavior</i> , 2017, 177, 122-128.	1.0	6
512	A systematic review of lifestyle counseling for diverse patients in primary care. <i>Preventive Medicine</i> , 2017, 100, 67-75.	1.6	16
513	Obesity and hypertension. <i>Pharmacological Research</i> , 2017, 122, 1-7.	3.1	430
514	Effects of obesity treatment on female reproduction: results do not match expectations. <i>Fertility and Sterility</i> , 2017, 107, 860-867.	0.5	32
515	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. <i>Current Diabetes Reports</i> , 2017, 17, 34.	1.7	36
516	Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. <i>Molecular Metabolism</i> , 2017, 6, 440-446.	3.0	87
517	Metabolic characteristics of Appalachian children. <i>Clinical Nutrition ESPEN</i> , 2017, 22, 36-42.	0.5	0
518	Current pharmacotherapies for obesity. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, S43-S52.	0.5	18
519	Pharmacological and non-pharmacological strategies for obese women with subfertility. <i>The Cochrane Library</i> , 2017, , .	1.5	0
521	Lorcaserin plus lifestyle modification for weight loss maintenance: Rationale and design for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2017, 59, 105-112.	0.8	13
522	Bench to bedside in appetite research: Lost in translation?. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 163-173.	2.9	6
523	Off-label drugs for weight management. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 223-234.	1.1	43
524	Role of the family doctor in the management of adults with obesity: a scoping review. <i>BMJ Open</i> , 2018, 8, e019367.	0.8	19
525	A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet. <i>Obesity</i> , 2018, 26, 299-309.	1.5	20
526	Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 801-805.	0.7	16

#	ARTICLE	IF	CITATIONS
527	Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. <i>Pediatric Diabetes</i> , 2018, 19, 191-198.	1.2	33
528	Obesity-induced changes in lipid mediators persist after weight loss. <i>International Journal of Obesity</i> , 2018, 42, 728-736.	1.6	33
529	Progress and challenges in anti-obesity pharmacotherapy. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 237-248.	5.5	210
530	Treatment of Obesity in Primary Care. <i>Medical Clinics of North America</i> , 2018, 102, 35-47.	1.1	24
531	The case for stepped care for weight management after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 112-116.	1.0	17
532	Impact of Body Image Perception on Weight Status: A Refuelling of Non-communicable Disease in Urban South African Zulu Women: Not Just Calipers, Tapes and Scales. , 0, , .		0
533	Metabolic Syndrome and Nutritional Interventions. , 2018, , 257-276.		0
534	The Use of Mobile Apps and SMS Messaging as Physical and Mental Health Interventions: Systematic Review. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 456-465.	0.4	8
535	Medical Management of Obesity. , 2018, , 379-402.		0
536	Combined Treatment for Obesity and Depression: A Pilot Study. <i>Obesity</i> , 2018, 26, 1144-1152.	1.5	31
537	Brown adipose tissue and lipid metabolism: New strategies for identification of activators and biomarkers with clinical potential. , 2018, 192, 141-149.		14
538	Barrier-belief lifestyle counseling in primary care: A randomized controlled trial of efficacy. <i>Patient Education and Counseling</i> , 2018, 101, 2134-2144.	1.0	2
539	Supplementation with Oligonol, Prevents Weight Gain and Improves Lipid Profile in Overweight and Obese Saudi Females. <i>Current Nutrition and Food Science</i> , 2018, 14, 164-170.	0.3	5
540	Early Weight Loss in Behavioral Treatment Predicts Later Rate of Weight Loss and Response to Pharmacotherapy. <i>Annals of Behavioral Medicine</i> , 2019, 53, 290-295.	1.7	19
541	Short-term Evidence in Adults of Anorexigenic Drugs Acting in the Central Nervous System: A Meta-Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1798-1815.	1.1	6
542	Effect of dose of behavioral weight loss treatment on glycemic control in adults with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000653.	1.2	12
543	A Toolbox Approach to Obesity Treatment in Urban Safety-Net Primary Care Clinics: a Pragmatic Clinical Trial. <i>Journal of General Internal Medicine</i> , 2019, 34, 2405-2413.	1.3	2
544	Quality in Obesity Treatment. , 2019, , .		3

#	ARTICLE	IF	CITATIONS
545	The MODELâ€”Intensive Behavioral Therapy Program: A Weight Control Blueprint for Health Care Practitioners. <i>Obesity</i> , 2019, 27, 1558-1559.	1.5	1
546	Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme. <i>Obesity Science and Practice</i> , 2019, 5, 468-478.	1.0	2
547	Low Carbohydrate and Low-Fat Diets: What We Don't Know and Why we Should Know It. <i>Nutrients</i> , 2019, 11, 2749.	1.7	47
548	Combination of GLPâ€”1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00082.	1.0	8
549	Cardiovascular risk and obesity. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 74.	1.2	236
550	Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 33.	7.1	343
551	A pilot study of acceptance-based behavioural weight loss for adolescents with obesity. <i>Behavioural and Cognitive Psychotherapy</i> , 2019, 47, 686-696.	0.9	20
552	Identifying and Addressing Individuals Resistant to Behavioral Lifestyle Treatment. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 354-358.	0.8	1
553	Primary Care Interventions for Obesity: Review of the Evidence. <i>Current Obesity Reports</i> , 2019, 8, 128-136.	3.5	49
554	Change in domain-specific but not general psychological flexibility relates to greater weight loss in acceptance-based behavioral treatment for obesity. <i>Journal of Contextual Behavioral Science</i> , 2019, 12, 59-65.	1.3	11
555	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 444-454.	0.4	1
556	Prognostic Value of Ultrasound Stratigraphy in Long-Term Weight Loss: Results from a Nutritional Counseling Program. <i>Obesity Facts</i> , 2019, 12, 606-617.	1.6	2
557	Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. <i>Obesity</i> , 2019, 27, 75-86.	1.5	63
558	Design of the Rural LEAP randomized trial: An evaluation of extended-care programs for weight management delivered via group or individual telephone counseling. <i>Contemporary Clinical Trials</i> , 2019, 76, 55-63.	0.8	11
559	Church-Based Social Supportâ€™s Impact on African-Americansâ€™ Physical Activity and Diet Varies by Support Type and Source. <i>Journal of Religion and Health</i> , 2019, 58, 977-991.	0.8	12
560	Obesity, Treatment of. , 2020, , 737-747.		0
561	Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. <i>International Journal of Obesity</i> , 2020, 44, 353-361.	1.6	26
562	Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 639-646.	1.1	9

#	ARTICLE	IF	CITATIONS
563	Lifestyle modification approaches for the treatment of obesity in adults.. American Psychologist, 2020, 75, 235-251.	3.8	199
564	Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial. Obesity Facts, 2020, 13, 572-583.	1.6	5
565	The risk of cardiovascular complications with current obesity drugs. Expert Opinion on Drug Safety, 2020, 19, 1095-1104.	1.0	14
566	Use of Home Enteral Nutrition in Malnourished Postâ€Bariatric Surgery Patients. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1023-1031.	1.3	6
567	Protocol for Partner2Lose: A randomized controlled trial to evaluate partner involvement on long-term weight loss. Contemporary Clinical Trials, 2020, 96, 106092.	0.8	4
568	Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Bingeâ€Eating Disorder: 12â€Month Followâ€up. Obesity, 2020, 28, 2116-2124.	1.5	19
569	Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial. PLoS ONE, 2020, 15, e0233876.	1.1	34
570	Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases. Molecules, 2020, 25, 1403.	1.7	26
571	A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093830.	1.4	55
572	Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity, 2020, 28, 529-536.	1.5	85
573	The Effectiveness of Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. SSRN Electronic Journal, 0, , .	0.4	0
574	A modern view on the prevention and treatment of arterial hypertension in obesity. Profilakticheskaya Meditsina, 2021, 24, 97.	0.2	2
575	MedikamentÃ¶se Therapie der Adipositas. Ã„rztliche Psychotherapie, 2021, 16, 16-21.	0.1	0
576	Pharmacological and non-pharmacological strategies for obese women with subfertility. The Cochrane Library, 2021, 2021, CD012650.	1.5	2
577	Antibiotic Followed by a Potential Probiotic Increases Brown Adipose Tissue, Reduces Biometric Measurements, and Changes Intestinal Microbiota Phyla in Obesity. Probiotics and Antimicrobial Proteins, 2021, 13, 1621-1631.	1.9	1
578	Development and Validation of New BODY-Q Scales Measuring Expectations, Eating Behavior, Distress, Symptoms, and Work Life in 4004 Adults From 4 Countries. Obesity Surgery, 2021, 31, 3637-3645.	1.1	7
580	Stair climbing activity and vascular function in patients with hypertension. Hypertension Research, 2021, 44, 1274-1282.	1.5	13
581	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gutâ€Liver Axis. Nutrients, 2021, 13, 2649.	1.7	24

#	ARTICLE	IF	CITATIONS
582	The effects of bariatric surgery on periconception maternal health: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2021, 27, 1030-1055.	5.2	20
583	Additional considerations in gynecologic care. , 2022, , 148-187.e6.		0
584	Awareness of non-alcoholic fatty liver disease is low in the general population of Saudi Arabia. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 899-905.	0.1	1
585	Obesity and Pharmacological Treatment. , 2007, , 167-171.		3
586	An Addiction Model of Binge Eating Disorder. , 2010, , 633-647.		3
587	Adaptive Responses to Weight Loss. , 2014, , 97-111.		4
588	Increasing Adherence to Diet and Exercise Through Cognitive Behavioural Strategies. , 2015, , 327-335.		2
589	Cardiovascular Benefits of Dietary Polyphenols. , 2020, , 239-257.		3
590	Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg. <i>Behaviour Research and Therapy</i> , 2020, 131, 103639.	1.6	17
591	Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2020, 22, 154-158.	0.4	5
592	Behavioral interventions for obesity in children and adults: Evidence base, novel approaches, and translation into practice.. <i>American Psychologist</i> , 2018, 73, 981-993.	3.8	52
593	Randomized controlled trial testing the effectiveness of adaptive "SMART" stepped-care treatment for adults with binge-eating disorder comorbid with obesity.. <i>American Psychologist</i> , 2020, 75, 204-218.	3.8	48
594	Week-to-week predictors of weight loss and regain.. <i>Health Psychology</i> , 2019, 38, 1150-1158.	1.3	23
595	Pediatric Obesity: Impact and Surgical Management. <i>Southern Medical Journal</i> , 2006, 99, 833-844.	0.3	10
596	Weight-loss treatment for OSA: medical and surgical options. , 2010, , 302-320.		2
597	Missing Data in Randomized Clinical Trials for Weight Loss: Scope of the Problem, State of the Field, and Performance of Statistical Methods. <i>PLoS ONE</i> , 2009, 4, e6624.	1.1	139
598	Weight Loss in Nonalcoholic Fatty Liver Disease Patients in an Ambulatory Care Setting Is Largely Unsuccessful but Correlates with Frequency of Clinic Visits. <i>PLoS ONE</i> , 2014, 9, e111808.	1.1	59
599	The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2014, 14, 98.	0.6	4



#	ARTICLE	IF	CITATIONS
600	The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2015, 15, 61.	0.6	4
601	The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2009, 53, 262-270.	1.3	21
602	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 373.	1.1	62
603	Emerging role of GLP-1 receptor agonists in the treatment of obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 263.	1.1	10
604	Current Burden of diabetes in Kingdom of Saudi Arabia in an epidemiological survey. <i>Egyptian Academic Journal of Biological Sciences C Physiology and Molecular Biology</i> , 2014, 6, 85-91.	0.0	7
605	The Role of Lifestyle Change in the Prevention and Treatment of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5270-5279.	0.9	31
606	To Text or Not to Text: Electronic Message Intervention to Improve Treatment Adherence Versus Matched Historical Controls. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11720.	1.8	3
607	Virtual Reality for Enhancing the Cognitive Behavioral Treatment of Obesity With Binge Eating Disorder: Randomized Controlled Study With One-Year Follow-up. <i>Journal of Medical Internet Research</i> , 2013, 15, e113.	2.1	116
608	Mobile Phone Apps to Promote Weight Loss and Increase Physical Activity: A Systematic Review and Meta-Analysis. <i>Journal of Medical Internet Research</i> , 2015, 17, e253.	2.1	463
609	The Use of Mobile Apps and SMS Messaging as Physical and Mental Health Interventions: Systematic Review. <i>Journal of Medical Internet Research</i> , 2017, 19, e295.	2.1	369
610	Weight Loss Associated With Different Patterns of Self-Monitoring Using the Mobile Phone App My Meal Mate. <i>JMIR MHealth and UHealth</i> , 2017, 5, e8.	1.8	42
611	Development of a Weight Loss Mobile App Linked With an Accelerometer for Use in the Clinic: Usability, Acceptability, and Early Testing of its Impact on the Patient-Doctor Relationship. <i>JMIR MHealth and UHealth</i> , 2016, 4, e24.	1.8	18
612	Insights From Google Play Store User Reviews for the Development of Weight Loss Apps: Mixed-Method Analysis. <i>JMIR MHealth and UHealth</i> , 2017, 5, e203.	1.8	35
613	High-Density Lipoprotein Cholesterol. , 2016, , 321-366.		2
614	High-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006, , 295-340.	0.0	2
615	Weight Loss Clinics. , 2008, , 593-605.		1
616	Weight Loss Interventions for Patients with Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 43-53.	1.4	7
617	Pharmacotherapy for obesity: What you need to know. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 951-958.	0.6	28



#	ARTICLE	IF	CITATIONS
618	Pharmacotherapies for Overeating and Obesity. <i>Journal of Genetic Syndromes &amp; Gene Therapy</i> , 2013, 04, 131.	0.2	12
619	Predictors of Successful Weight Loss Maintenance: A Qualitative Comparative Analysis. <i>Open Journal of Preventive Medicine</i> , 2014, 04, 257-269.	0.2	2
620	Obesity management and scientific evidence. <i>Journal of the Korean Medical Association</i> , 2011, 54, 250.	0.1	5
621	Effect of JYTK on Antioxidant Status and Inflammation in Patients With Type 2 Diabetes: A Randomized Double-Blind Clinical Trial. <i>International Journal of Endocrinology and Metabolism</i> , 2016, 14, e34400.	0.3	4
622	Effects of Weight Management Program for Middle Aged Women with Metabolic Syndrome Risk Factors. <i>The Korean Journal of Obesity</i> , 2014, 23, 106.	0.2	6
623	Effect of Curcumin on Glycaemic and Lipid Parameters in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Reproductive Sciences</i> , 2022, 29, 3124-3133.	1.1	4
625	Obesity and Lifestyle Modification. <i>Fundamental and Clinical Cardiology</i> , 2006, , 63-78.	0.0	0
626	Impacto do tratamento de sobrepeso/obesidade sobre os nÃveis de pressÃo arterial na AtenÃÃo PrimÃria Ã SaÃde. <i>Revista Brasileira De Medicina De FamÃlia E Comunidade</i> , 2006, 2, 217-227.	0.1	0
628	Pharmacological Treatment of the Overweight Patient. , 2007, , 203-256.		1
629	Behavior Modification. , 2007, , 173-184.		0
631	MedikamentÃrse Therapie der Adipositas. , 2008, , 341-347.		0
632	Brief Therapies. , 2008, , 101-115.		0
633	Adjunctive and Alternative Treatments of Sleep-Related Breathing Disorders. , 2008, , 443-451.		0
634	Obesity and In Vitro Fertilization (IVF) Outcomes. , 2009, , 185-191.		0
635	Long-Term Impact of Weight Loss on Obesity and Obesity-Associated Comorbidities. , 2009, , 347-368.		0
636	OBSESITY AND NUTRITION. , 2009, , 549-555.		0
637	ÃCuÃl es el tratamiento no farmacolÃgico con mejores resultados en obesidad?. <i>Medwave</i> , 2009, 9, .	0.2	0
640	Pharmacotherapy of Childhood Obesity and Pre-diabetes. , 2010, , 339-355.		0

#	ARTICLE	IF	CITATIONS
641	Obesidad: epidemiología actual y futura. Medwave, 2010, 10, .	0.2	0
642	Obesity and Therapeutic Approaches to Weight Loss. , 2011, , 91-106.		0
644	Assessment and Treatment of Excess Weight. , 2012, , 29-45.		0
646	Adipositas. Springer-Lehrbuch, 2012, , 623-627.	0.1	0
647	Risk Markers for Atherothrombotic Disease. , 2012, , 914-934.		6
649	Diet Quality and Use of a Personal Digital Assistant: Transitioning from the Standard Paper Diary to Electronic Diaries. , 2013, , 353-363.		0
650	Approaching young patient with obesity in family practice. Saudi Journal of Obesity, 2013, 1, 10.	0.3	1
651	Individual interventions to treat obesity. , 2014, , 84-102.		0
653	Assessment of the Obese Patient. , 2014, , 167-187.		0
654	Evaluation and Treatment of Obesity in Primary Care. , 2014, , 271-286.		0
655	Obesity in the Tropics. , 2014, , 1168-1176.e1.		0
657	Factors Affecting Readiness to Change among Literate Obese Patients in Primary Care. American Journal of Applied Psychology, 2015, 4, 105.	0.1	0
658	Adipositas. Springer-Lehrbuch, 2016, , 669-673.	0.1	0
659	Symptom Management: Weight Gain. , 2016, , 241-269.		1
660	Características clínicas y demográficas de pacientes sometidos a cirugía bariátrica en Medellín. Medicina UPB, 2016, 35, 81-88.	0.1	2
661	ORLISTAT AND PHENTERMINE IN WEIGHT LOSS IN SELECTED CZECH POPULATION. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2016, 85, 13-18.	0.2	0
662	Advances in Pharmacological Treatment of Pediatric Obesity. , 2016, , 333-351.		0
663	Endoluminal Procedures for the Treatment and Management of Bariatric Patients. , 2017, , 127-138.		0

#	ARTICLE	IF	CITATIONS
664	Combining CBT-OB with Weight-Loss Drugs and Bariatric Surgery. , 2018, , 211-220.		0
665	Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome. <i>Jornal Brasileiro De Reproducao Assistida</i> , 2018, 22, 180-184.	0.3	4
667	Evidence for Nutrition Counseling in the Care of Patients with Obesity. , 2019, , 79-99.		0
668	Effect of aerobics on weight and fat mass loss in adult women: Systematic review and meta-analysis. <i>Acta Gymnica</i> , 2019, 49, 144-152.	1.1	1
669	Weight Loss Medications in Adolescents. <i>Contemporary Endocrinology</i> , 2020, , 325-333.	0.3	0
670	Obesity as a component of the metabolic syndrome and the condition of periodontic tissues. <i>Problems of Uninterrupted Medical Training and Science</i> , 2020, 38, 31-33.	0.1	0
671	Antiobesity drugs for obese women planning pregnancy. , 2020, , 301-306.		1
672	Nutritional Monitoring and Advising Information System for Healthcare Support. , 0, , 636-651.		0
674	Obesity Prevention During Adulthood. , 2007, , 489-514.		0
675	Assessment of the Obese Patient. , 2014, , 167-187.		0
676	Evaluation and Treatment of Obesity in Primary Care. , 2014, , 271-286.		0
677	Adaptive Responses to Weight Loss. , 2014, , 97-111.		0
681	Weight Management in Diabetes Prevention. , 2007, , 243-263.		1
682	Obesity and Its Treatment in Type 2 Diabetes. , 2008, , 333-350.		0
683	Sleep and Quality of Life in Obesity. , 2008, , 445-452.		0
685	A diet and exercise program to improve clinical outcomes in patients with obstructive sleep apnea—a feasibility study. <i>Journal of Clinical Sleep Medicine</i> , 2009, 5, 409-15.	1.4	39
686	Evaluating an insurance-sponsored weight management program with the RE-AIM Model, West Virginia, 2004-2008. <i>Preventing Chronic Disease</i> , 2010, 7, A46.	1.7	18
687	Tackling obesity: new therapeutic agents for assisted weight loss. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 95-112.	1.1	4



#	ARTICLE	IF	CITATIONS
715	The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. <i>Obesity Surgery</i> , 2022, 32, 3280-3288.	1.1	23
716	Dietary adaptation for weight loss maintenance at Yale (DAWLY): Protocol and predictions for a randomized controlled trial. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
717	Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211271.	1.4	6
718	Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 927-937.	4.0	20
720	Long-term effects on weight loss and maintenance by intensive start with diet and exercise. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2023, 33, 246-256.	1.3	4
722	Inability to Understand the Complexity of Maintaining Weight Loss and the Complications. , 0, , .		0
723	Therapeutics in Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 255-273.	0.8	0
724	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	5
725	Role of nanomedicine for targeted drug delivery in life-threatening diseases. , 2023, , 189-217.		0
726	Combined lifestyle interventions. , 2023, , 333-351.		0
727	Cardiometabolic risk factors efficacy of semaglutide in the STEP program. <i>Postgraduate Medicine</i> , 2022, 134, 18-27.	0.9	1
728	Current and emerging medications for the management of obesity in adults. <i>Medical Journal of Australia</i> , 2023, 218, 276-283.	0.8	5
729	Telehealth acceptance and commitment therapy for weight loss: Protocol of the WeLNES full scale randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2023, 126, 107091.	0.8	0
730	Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. <i>Postgraduate Medicine</i> , 2022, 134, 1-4.	0.9	1
731	Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 1-24.	1.5	14
739	Infertility care of the PCOS patient. , 2024, , 105-123.		0
741	The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. <i>Current Obesity Reports</i> , 2023, 12, 453-473.	3.5	5